

Enabling earlier and faster cancer diagnosis across the NHS

C the Signs PSA Surveillance Pricing Document

Platform Overview

C the Signs is an AI-driven cancer detection platform designed to identify patients at risk of cancer earlier, standardise referral decision-making, and optimise access to diagnostics across the NHS, to support end-to-end cancer detection, surveillance, and moving care into the community without creating a burden on primary care.

C the Signs PSA Surveillance is a structured, digital service designed to support safe, consistent, and proactive management of patients requiring Prostate Specific Antigen (PSA) monitoring. It addresses the clinical complexity of PSA interpretation and the operational challenge of tracking large numbers of patients requiring repeat PSA testing for cancer suspicion and prostate cancer monitoring across multi-care settings. By providing a single, standardised view of PSA surveillance activity across organisations, the service reduces clinical risk, missed follow-up and improves early identification of concerning trends.

C the Signs PSA Surveillance introduces a dedicated PSA dashboard, enabling clinicians and administrative teams to manage all patients requiring PSA follow-up and automates workflows. Patients can be onboarded using their NHS number, with capture of key clinical context including diagnosis, diagnosis date, recall frequency, and optional custom PSA thresholds aligned to local protocols. Including configurable clinical protocols, automated symptom questionnaires, view patient PSA follow-up plan, access results, and engage more actively in their care.

The service integrates directly with the electronic health record, automatically pulling PSA test results into the dashboard. For each patient, the dashboard provides clear visibility of when a PSA test is due, the date and value of PSA results, and a longitudinal view of PSA trends over time. This enables clinicians to identify abnormal results, detect rising PSA values below defined thresholds, and take timely action based on agreed clinical protocols. It includes automated safety-netting to track patients across testing, review, referral, and outcomes, ensuring no patient is lost to follow-up.

Where patients who exceed their individually personalised PSA thresholds are referred back for urological review or if results indicate possible cancer, clinicians can initiate urgent suspected cancer (USC) referrals directly through the platform, with standardised referral outputs and pre-referral requirements completed and coded back to the patient record. This ensures continuity of surveillance, safety-netting and follow-up with automated workflows and clarity of clinical responsibility. Patients with a confirmed prostate cancer diagnosis are automatically reflected within the confirmed cancer dashboard, supporting ongoing surveillance and care planning.

Real-time dashboards provide visibility of PSA surveillance activity and outcomes at practice, PCN, ICB, hospital and system level, supporting quality improvement and pathway optimisation. Together, C the Signs PSA Surveillance provides a scalable, data-driven approach to managing PSA testing in primary care, improving patient safety, supporting earlier detection, and reducing administrative burden across the NHS.

PSA Surveillance

PSA Surveillance capabilities

Dedicated PSA surveillance dashboard: A purpose-built PSA tab within the C the Signs Practice Dashboard, enabling standardised management of patients requiring PSA monitoring in primary care.

Integrated PSA data from the EHR: Automatically pulls PSA test results into the dashboard, reducing manual tracking and improving reliability.

Enrolment patients using NHS number: Allows clinicians or administrators to add patients requiring PSA surveillance, including screening, benign disease, or confirmed prostate cancer.

Configurable diagnosis and clinical context: Supports capture of diagnosis (prostate cancer, BPH, or other), diagnosis date, and optional PSA thresholds to guide follow-up and escalation.

PSA recall scheduling: Enables structured recall intervals (one-off, monthly, 3-monthly, 6-monthly, or annual), with automatic calculation of when the next PSA is due.

PSA due and PSA requested visibility: Clear visibility of when PSA tests are due and when they have been requested, supporting proactive follow-up and reducing missed tests.

PSA result trend analysis: Displays PSA results over time in a tabular view, enabling identification of rising PSA values even when below predefined thresholds.

Abnormal PSA identification: Flags PSA results that exceed defined thresholds to support timely clinical review and action.

Clinical outcomes and escalation pathways: Supports recording of outcomes, including urgent suspected cancer referrals, with automatic movement of patients into the active cancer pathway where appropriate.

Alignment with confirmed cancer tracking: Automatically adds patients with a prostate cancer diagnosis to the confirmed cancer dashboard if not already present, ensuring continuity of care and surveillance.

Training and Education Support

C the Signs provides continuous training and education to support implementation and sustain high engagement, includes:

- Attendance at PCN and practice meetings, local cancer events, and secondary care educational sessions
- Dedicated Training webinars
- Workshops to interpret performance metrics and identify areas for improvement.

Technical Support and Maintenance

Helpdesk available 9am–5pm, Monday to Friday (excluding Bank Holidays):

- Remote deployment and maintenance across all practices
- Security and compliance managed in line with NHS Digital and IG requirements
- Continuous updates to align with evolving NICE guidelines and national policies.

Supporting Local Cancer Teams and Pathways

C the Signs collaborates with local cancer teams to:

- Attend alliance and ICB cancer meetings
 - Provide routine data reports aligned with local KPIs
 - Support pathway redesign and the adoption of new diagnostic services
- Facilitate local implementation

Deployment and Governance

Each deployment follows a robust implementation plan, including:

- Information Governance approvals (DPIA & DPA)
- Local configuration of pathways and resources
- Comprehensive communication and engagement plan
- Webinars and live training prior to go-live
- Steering Group oversight with agreed KPIs and data monitoring

Licensing Model

C the Signs PSA Surveillance is commissioned as an annual licensing model, based on the registered patient population within a defined area. All prices below exclude VAT:

PSA Surveillance Licence cost:

Length of Licence	Per Patient Cost (£)
1 year	0.36p
2 Year	0.32p
3 Year	0.30p

The licence covers all configuration, deployment, and ongoing support, including:

- Configuration of regional cancer pathways and access to services
- Onboarding of all GP practices
- Training and education support for all practices and PCNs throughout the licence period
- Technical support and system maintenance, with a dedicated helpdesk

Customers already using the C the Signs Clinical Decision Support platform can add the PSA Surveillance service at a discounted rate, reflecting reduced deployment and maintenance costs and the use of existing technical infrastructure.

Licence cost for Clinical Decision Support customers:

Length of Licence	Per Patient Cost (£)
1 year	0.16p
2 Year	0.12p
3 Year	0.10p